2015


To access this material please log in or register

Register Authorize
2015/№6

Trends of arterial hypertension in russia: is there a progress in prescription of antihypertensive therapies? (results of studies in 1993–2013)

Shalnova S. A., Deev A. D., Balanova Yu. A., Kapustina A. V., Konstantinov V. V., Muromtseva T. A., Boytsov S. A.
Federal State Budgetary Institution, “National Research Center for Preventive Medicine” of the RF Ministry of Health Care, Petroverigsky Per. 10, Bldg. 3, Moscow 101990

Keywords: hyperpiesis, treatment, RF, epidemiology

DOI: 10.18087/rhj.2015.6.2145

Background. Prevalence of AH in the world varies from zero to more than 50%. At present time, it is well known that decreasing BP can restrict progression of renal insufficiency, development of MI, stroke, cardiovascular mortality, and all-cause mortality resulting from hypertension. Aim. Epidemiological analysis of prevalence of hypertension and drug therapies used in the Russian practice in recent 20 years, from 1993 to 2013. Materials and methods. The study was performed on three samples of Russian population aged 25–64 who were evaluated in 1992–94, 2003–2004, and 2012–14. The total number of evaluated persons was 64 819 including 26 051 men. Protocols of all three studies included general procedures (measurement of BP, heart rate, height, body weight, waist circumference) and questions on awareness, prescription medication, and BP. BP and heart rate, and anthropometrics were measured. In two studies, additional laboratory tests were performed. Results. A small but significant increase in AH incidence was observed in 2013 (44 %) compared with previous data due to an increase in AH among males. In 1993, the prevalence of AH among 25–64 years old men was 43 %; in 2003 – 36.1 %, and in 2013 – 48.2 %. In females, a sustained decrease in AH incidence from 48.6 to 40.8 % has been observed starting from 1993. Coverage of hypertensive men with the treatment was considerably less than of women. However, the effectiveness of treatment increased more than four times, 7 times for men and 3 times for women, in 2013 vs. 1993, although remained insufficient. Three common significant indices were isolated among factors associated with insufficient effectiveness of therapy: low level of education, obesity, and high heart rate. The choice of antihypertensive drugs (AHD) has considerably changed for 20 years. In 1993, central action drugs prevailed, with clonidine accounting for 17.1% of them and rauwolfia – for 47.7%. In 2013, RAAS inhibitors were the most often prescribed drugs, more than 70%. Notably, more than 50% of patients received a monotherapy. Conclusion. Issues of prescription and use of AHD should be continuously monitored in this country, which will allow detecting improper trends in the treatment of hypertension and taking actions for their correction in a timely fashion.
  1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360 (9349):1903–13.
  2. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. Effect of blood pressure lowing and antihypertensive drug class on progression of hypertensive kidney disease: result from the AASK trial. JAMA. 2002 Nov 20;288 (19):2421–31.
  3. Evans JG, Rose GA. Hypertension. Br Med Bull. 1971 Jan;27 (1):32–42.
  4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH / ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul;34 (28):2159–219.
  5. Чазова И. Е., Ратова Л. Г., Бойцов С. А., Небиеридзе Д. В. Диагностика и лечение артериальной гипертензии (Рекомен­дации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010;3:5–26.
  6. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Panor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003 May 21;289 (19):2534–44.
  7. Шальнова С. А., Деев А. Д., Вихирева О. В., Оганов Р. Г. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001;2:3–7.
  8. Оганов Р. Г., Тимофеева Т. Н., Колтунов И. Е., Константинов В. В., Баланова Ю. А., Капустина А. В. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваскулярная терапия и профилактика. 2011;10 (1):9–13.
  9. Чазова И. Е., Жернакова Ю. В., Ощепкова Е. В., Шальнова С. А., Яровая Е. Б., Конради А. О. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в Российской популяции больных артериальной гипертонией. Кардиология. 2014;54 (10):4–12.
  10. Бойцов С. А., Баланова Ю. А., Шальнова С. А., Деев А. Д., Артамонова Г. В., Гатагонова Т. М. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13 (4):4–14.
  11. Zohoori N, Mroz TA, Popkin B, Glinskaya E, Lokshin M, Mancini D et al. Monitoring the economic transition in the Russian Federation and its implications for the demographic crisis. The Russian Longitudinal Monitoring Survey. World Dev. 1998;26 (11):1977–93.
  12. Константинов В. В., Шальнова С. А., Деев А. Д., Тимофеева Т. Н., Капустина А. В., Баланова Ю. А. и др. Методические аспекты мониторирования эпидемиологической ситуации по артериальной гипертонии среди населения Российской Федерации в ходе выполнения целевой Федеральной программы «Профилактика и лечение артериальной гипертонии в Российской Федерации на 2002–2008 гг.». Кардиоваскулярная терапия и профилактика. 2007;6 (2):66–70.
  13. Бойцов С. А., Чазов Е. И., Шляхто Е. В., Шальнова С. А., Конради А. О., Карпов Ю. А. и др. Научно-организационный комитет проекта ЭССЕ-РФ Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая медицина. 2013;16 (6):25–34.
  14. Reklaitiene R, Tamosiunas A, Virviciute D, Baceviciene M, Luksiene D. Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983–2009. BMC Cardiovasc Disord. 2012 Aug 31;12:68.
  15. Dorobantu M, Darabont RO, Badila E, Ghiorghe S. Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study. Int J Hypertens. 2010 Feb 1;2010:970694.
  16. Bielecka-Dabrowa A, Aronow W, Rysz J, Banach M. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep. 2011 Apr;5 (2):174–9.
  17. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013 Aug 30;3 (8):e003423.
  18. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4 (6):393–404.
  19. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003 Mar 21;289 (19):2534–44.
  20. Shkolnikov VM, Andreev EM, McKee M, Leon DA. Components and possible determinants of decrease in Russian mortality in 2004–2010. Demogr Res. 2013 Jan-Jun;28:917–50.
  21. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medi­cation use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012 Oct 23;126 (17):2105–14.
  22. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ. 2003 Jun 28;326 (7404):1427.
  23. Moser M. Rationale for combination therapy in the management of hypertension. J Clin Hypertens (Greenwich). 2003 Nov-Dec;5 (6 Suppl 4):17–25.
Shalnova S. A., Deev A. D., Balanova Yu. A., Kapustina A. V., Konstantinov V. V., Muromtseva T. A. et al. Trends of arterial hypertension in russia: is there a progress in prescription of antihypertensive therapies? (results of studies in 1993–2013). Russian Heart Journal. 2015;14 (6):389–396

To access this material please log in or register

Register Authorize
Ru En